2 days ago
1
Dmitry Vinogradov
Oppenheimer has initiated Monopar Therapeutics at outperform citing the potential of a candidate for the genetic disorder Wilson disease it acquired from AstraZeneca (AZN).
The firm set a $77 price target (~127% upside based on Sept. 2 close).
Analyst Andreas
English (US) ·